40
The Spanish Competition Authority (CNMC) has imposed a fine of €10.25 million on the Leadiant group (Essetifin SpA, Leadiant Biosciences Ltd and Leadiant GmbH, jointly referred as Leadiant) for abusing its dominant position as the marketer of the sole medicine available in Spain for the (...)